Google AI
NewsPronto

 

ACN Newswire

Read more press releases from ACN Newswire here

Nanobiotix Reports Successful Results from Phase I/II Trial of NBTXR3 in Head Neck Cancer

  • Written by: ACN Newswire

image

- Primary safety and feasibility endpoints achieved - Preliminary positive signs of antitumoral effect in all evaluable patients- Company preparing now registration clinical plan, including EU and USA

Paris, France, Cambridge, MA, Jul 7, 2016 - (ACN Newswire) - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine...

Read more: Nanobiotix Reports Successful Results from Phase I/II Trial of NBTXR3 in Head Neck Cancer